Loading...
01/11 03:32
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with double-digit growth in Latin America and a 27% growth in European direct markets. Despite challenges in China, the U.S. market shows good growth and market share gains. Positive guidance for U.S. revenues and strategic focus on account expansion and utilization suggest a positive outlook. The Q&A session confirms strong U.S. growth, premium pricing, and effective inventory strategies, though some uncertainties remain regarding China. Given the company's small-cap status, the stock is likely to react positively in the short term.
Revenue Revenue in the second quarter totaled $51.3 million, a growth of 16% over last year. Excluding the positive impact of foreign exchange, growth would have been approximately 14.3% versus a year ago. Reasons for growth include higher margin sales in the United States and strong performance in direct markets.
U.S. Revenue Second quarter sales in the United States were $10.3 million, exceeding the $9.5 million to $10 million range provided earlier. U.S. revenue is expected to exceed $40 million for the year. Growth is attributed to the superior product benefits of Motiva and successful account acquisition.
European Direct Market Sales Sales in European direct markets increased by approximately 27% this quarter, excluding the benefit of currency and the acquisition of the Benelux distributor. Growth reflects a new sales record and improved operational processes.
Gross Profit Gross profit for the second quarter was $35.3 million or 68.8% of revenue, a 320 basis point increase compared to the 65.6% of revenue for the same period in 2024. The increase reflects higher margin sales in the United States.
Adjusted EBITDA Adjusted EBITDA loss for the quarter was $8.5 million, an improvement from the $12.1 million in the first quarter. The improvement is due to better operating profitability and reduced expenses.
Cash Use Cash use fell to $14.5 million from $21.2 million last quarter. The reduction is attributed to improved cash flow management and operational efficiencies.
Operating Expenses Total operating expenses for the second quarter increased by approximately $11.1 million from the year-ago period to $49.4 million. The increase was primarily due to the ramp-up of commercial activity in the United States, including the Megan Trainer campaign and higher shipping costs.
Latin American Distributors Latin American distributors grew double digits in the second quarter. Stabilization in Brazil and strong growth in Argentina contributed to this performance.
Asia Pacific Sales Asia Pacific sales were 15% of total sales. While there was sequential growth, results were down year-over-year, mostly due to challenges in China and timing of orders from other distributors.
Motiva Flora SmoothSilk Tissue Expander: Won both the Innovation and the Safety Awards in the 2025 Medical Device Network Excellence Awards, establishing it as a benchmark in breast reconstructive surgery.
Preservé: An advanced, less invasive breast enhancement technique designed to preserve natural breast tissue functionality, including nipple sensation and chest muscles. It provides fast post-procedure recovery and is expected to launch in the U.S. in the first half of 2026.
Motiva implants: Clear benefits in breast procedures, especially with smaller implants and prefectoral positions. Expanded range of sizes expected to be FDA-approved in early 2026.
U.S. Market: Revenue in Q2 totaled $10.3 million, exceeding expectations. U.S. revenue is expected to exceed $40 million in 2025. The company has reached over 1,000 accounts in the U.S., with significant growth potential.
European Direct Markets: Sales increased by approximately 27% in Q2, driven by key markets like the U.K., Spain, and Germany.
Latin America: Stabilization in Brazil and strong growth in Argentina. Latin American distributors grew double digits in Q2.
China: Facing challenges but remains a focus area. Motiva is the leading implant across Asia, with plans to achieve the same position in China.
Profitability and Cash Flow: Adjusted EBITDA loss improved to $8.5 million in Q2 from $12.1 million in Q1. Cash use reduced to $14.5 million from $21.2 million last quarter. The company expects its first positive EBITDA quarter later this year and aims for cash flow breakeven in 2026.
Operational Efficiency: Restructured OUS organization, reallocated resources, and applied improved operational processes, leading to benefits in direct markets.
Minimally Invasive Portfolio: Focus on areas with the most financial potential, such as the U.S. and minimally invasive products, while reducing expenses in other areas.
Digital and Social Media Strategy: Leveraging platforms like Instagram and TikTok to attract surgeons and patients, resulting in increased demand for Motiva implants.
China market challenges: China has been affected by a number of factors, and the company is working with its distribution partner and their investor to ensure success in the region. This indicates operational and market-specific challenges in China.
Cash flow and profitability: The company is currently operating at a loss, with an adjusted EBITDA loss of $8.5 million for the quarter. Although there is improvement, the company is still working towards achieving positive EBITDA later this year and cash flow breakeven by 2026.
Shipping and operational costs: Higher shipping costs, including air shipments to match demand and last-mile shipping costs in the U.S., have increased operational expenses. This could impact profitability if not managed effectively.
Regulatory and market approval: The company is awaiting FDA approval for an expanded range of sizes and breast reconstruction indications, which are critical for future growth. Delays or issues in regulatory approval could hinder strategic objectives.
Economic and market-specific risks: The company faces economic uncertainties in regions like Latin America, where stabilization efforts are ongoing in Brazil, and growth is dependent on market-specific factors.
Competitive pressures: The company is heavily reliant on surgeon adoption of Motiva implants, which involves a gradual process. Competitive pressures from other implant providers could slow down market penetration.
Revenue Guidance: The company has raised its revenue guidance for 2025 to a range of $208 million to $212 million, representing growth of 25% to 28%. This includes an expectation of at least $40 million in U.S. Motiva sales and single-digit growth outside the United States.
Sequential Growth Expectation: The company expects sequential growth in the third quarter of 2025, despite the traditional Q3 lull in plastic surgeries.
Profitability and Cash Flow: The company expects its first positive EBITDA quarter later in 2025 and remains on track to achieve cash flow breakeven in 2026. Cash use is expected to reduce by approximately $5 million per quarter for the next several quarters.
U.S. Market Growth: The U.S. market is expected to be the primary engine of growth in 2025, with higher surgeon utilization and the addition of accounts driving growth into 2026. Approval of additional sizes in early 2026 is expected to further accelerate growth.
Preservé Launch: The Preservé procedure is expected to launch in the U.S. in the first half of 2026, commanding a premium price and contributing to gross margin expansion and TAM growth.
Innovation Pipeline: The company plans to bring a cycle of innovation to the U.S. market over the next few years, including minimally invasive procedures and advancements in breast reconstruction.
Global Market Trends: Growth in direct markets outside the U.S. is expected to continue, with European direct markets growing approximately 27% in Q2 2025. Preservé and Mia are expected to contribute meaningfully to growth in international markets.
The selected topic was not discussed during the call.
The earnings call highlights strong financial performance with record high revenue, positive EBITDA, and increased cash position. The company raised its revenue guidance and expects continued growth in the U.S. and international markets. The Q&A session confirmed positive momentum, strong market share goals, and strategic expansions. Despite some uncertainties, the overall sentiment is very positive, especially with significant growth expectations and strategic initiatives in place. Given the company's small-cap status, a strong positive stock price reaction is anticipated.
The earnings call highlights strong financial performance with double-digit growth in Latin America and a 27% growth in European direct markets. Despite challenges in China, the U.S. market shows good growth and market share gains. Positive guidance for U.S. revenues and strategic focus on account expansion and utilization suggest a positive outlook. The Q&A session confirms strong U.S. growth, premium pricing, and effective inventory strategies, though some uncertainties remain regarding China. Given the company's small-cap status, the stock is likely to react positively in the short term.
The earnings call highlights several positive factors: a 41% revenue increase, improved gross profit margins, and reduced net loss and EBITDA loss compared to the previous year. The company has a strong cash position and expects significant revenue growth in 2025. However, competitive pressures and foreign currency volatility pose risks. The absence of a shareholder return plan is offset by operational improvements and positive guidance. Given the small market cap, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.
Basic Financial Performance: 3 - Revenue growth and reduced losses are positive, but a registered direct offering and supply chain issues are concerning.\nProduct Development and Business Update: 3 - Positive FDA approval, but regulatory delays and demand fluctuations are negative.\nMarket Strategy: 3 - Expansion plans are promising, but economic conditions pose risks.\nExpenses and Financial Health: 3 - Decreased expenses are good, but increased operational activity raises concerns.\nShareholder Return Plan: 2 - Registered direct offering at a discount is negative.\nQ&A insights: Analysts showed cautious optimism, but uncertainties remain.\nConsidering market cap, a neutral stock price movement is expected.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
